beta-YohimbineCAS# 549-84-8 |
- alpha-Yohimbine
Catalog No.:BCN6166
CAS No.:131-03-3
- Yohimbine
Catalog No.:BCN2293
CAS No.:146-48-5
- Isorauhimbine
Catalog No.:BCN5578
CAS No.:483-09-0
- Allo-Yohimbine
Catalog No.:BCN3487
CAS No.:522-94-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 549-84-8 | SDF | Download SDF |
| PubChem ID | 2866 | Appearance | Powder |
| Formula | C21H26N2O3 | M.Wt | 354.5 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | methyl 18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate | ||
| SMILES | COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O | ||
| Standard InChIKey | BLGXFZZNTVWLAY-UHFFFAOYSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Beta-Yohimbine has anti-plasmodial and anti-malarial activity. 2. Beta-Yohimbine has approximately twice as toxic as yohimbine and corynanthine about one fifth as toxic. 3. Beta-yohimbine has alpha-1 and alpha-2 adrenoceptor blocking activities, it has cardiovascular effects. |
| Targets | Adrenergic Receptor | Antifection |
beta-Yohimbine Dilution Calculator
beta-Yohimbine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8209 mL | 14.1044 mL | 28.2087 mL | 56.4175 mL | 70.5219 mL |
| 5 mM | 0.5642 mL | 2.8209 mL | 5.6417 mL | 11.2835 mL | 14.1044 mL |
| 10 mM | 0.2821 mL | 1.4104 mL | 2.8209 mL | 5.6417 mL | 7.0522 mL |
| 50 mM | 0.0564 mL | 0.2821 mL | 0.5642 mL | 1.1283 mL | 1.4104 mL |
| 100 mM | 0.0282 mL | 0.141 mL | 0.2821 mL | 0.5642 mL | 0.7052 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Quercetin 3-O-beta-D-xylopyranoside
Catalog No.:BCN2851
CAS No.:549-32-6
- 8-Oxyberberine
Catalog No.:BCN3135
CAS No.:549-21-3
- Amitriptyline HCl
Catalog No.:BCC5033
CAS No.:549-18-8
- Arborinine
Catalog No.:BCN7438
CAS No.:5489-57-6
- PD 334581
Catalog No.:BCC6300
CAS No.:548756-68-9
- Sanshodiol
Catalog No.:BCN6577
CAS No.:54854-91-0
- Protogracillin(P)
Catalog No.:BCC8352
CAS No.:54848-30-5
- Roseoside
Catalog No.:BCN5728
CAS No.:54835-70-0
- Daphneolone
Catalog No.:BCN3230
CAS No.:54835-64-2
- Protoveratrine B
Catalog No.:BCN2435
CAS No.:124-97-0
- Trichodesmine
Catalog No.:BCN2145
CAS No.:548-90-3
- Gyrophoric acid
Catalog No.:BCN5731
CAS No.:548-89-0
- Phytolaccagenic acid
Catalog No.:BCN8090
CAS No.:54928-05-1
- Shikalkin
Catalog No.:BCC8359
CAS No.:54952-43-1
- 2-Oxopomolic acid
Catalog No.:BCN5732
CAS No.:54963-52-9
- Florilenalin
Catalog No.:BCN6422
CAS No.:54964-49-7
- Albendazole
Catalog No.:BCC3718
CAS No.:54965-21-8
- Tamoxifen Citrate
Catalog No.:BCC4382
CAS No.:54965-24-1
- Physalin D
Catalog No.:BCN7919
CAS No.:54980-22-2
- Shikonin acetyl
Catalog No.:BCN2452
CAS No.:54984-93-9
- 3,3'',5-Triiodo-L-thyronine Sodium Salt
Catalog No.:BCN1419
CAS No.:55-06-1
- HYOSCINE HYDROCHLORIDE
Catalog No.:BCN8331
CAS No.:55-16-3
- Benzamide
Catalog No.:BCN5737
CAS No.:55-21-0
- Epinephrine HCl
Catalog No.:BCC4319
CAS No.:55-31-2
Interaction between yohimbine alkaloids and amphetamine in mice.[Pubmed:402675]
Psychopharmacology (Berl). 1977 Jan 31;51(2):209-12.
The toxicity (LD50) of the isomers yohimbine, beta-Yohimbine, and corynanthine was determined in mice. The LD50 of amphetamine in the presence of a constant dose of a yohimbine isomer and that of the isomer in the presence of a constant dose of amphetamine were determined in aggregated mice. Isobolograms were constructed from these data and used to evaluate the interaction of the yohimbine alkaloids and amphetamine. beta-Yohimbine was found to be approximately twice as toxic as yohimbine and corynanthine about one fifth as toxic. There was a mutual potentiation between the toxicities of yohimbine and amphetamine. Potentiation of the toxicity of amphetamine occurred with beta-Yohimbine but the effect was not as marked as with yohimbine. In contrast, corynanthine antagonized the toxicity of amphetamine. The interaction between yohimbine and amphetamine is unlikely to be due to noradrenergic mechanisms but could conceivably involve serotonergic or dopaminergic mechanisms.
Structure-activity relationship of yohimbine and its related analogs in blocking alpha-1 and alpha-2 adrenoceptors: a comparative study of cardiovascular activities.[Pubmed:1976443]
Chem Pharm Bull (Tokyo). 1990 Jun;38(6):1702-6.
We investigated the selectivities and structure requirements for alpha-1 and alpha-2 adrenoceptor blocking activities of yohimbine (YO) and its 12 related analogs, such as beta-Yohimbine (beta-YO), dihydrocorynantheine (DHC) and (-)indoloquinolizidine ((-)IQ). The affinity of YO analogs to alpha-adrenoceptor was assessed by measuring their blockade of pressor responses to epinephrine in pithed rats. Among YO structure groups, the potency order was YO greater than DHC = beta-YO greater than geissoschizine methylether greater than 14 beta-hydroxy YO greater than 14 beta-benzoyloxy YO (inactive). (-)IQ was slightly less potent than YO, but much stronger than (+)IQ. Among (+/-)IQ structure groups, the potency order was (+/-)IQ greater than (+/-)1,12b-trans-1-hydroxy IQ much greater than (+/-)1,12b-cis-1-hydroxy IQ (inactive). (+/-)Borrerine was active, but (+/-)desmethylborrerine was inactive. The alpha-1 blocking activities of the four compounds YO, beta-YO, DHC and (-)IQ, were assessed in experiments of pressor responses to methoxamine in pithed rats and contractile responses to methoxamine in the rat vas deferens. The potency order was (-)IQ greater than YO greater than DHC greater than beta-YO. Furthermore, the alpha-2 blocking activities of the four analogs were assessed in experiments of pressor responses to clonidine and inhibition of electrically driven cardioacceleration by clonidine, in pithed rats. The potency order was YO greater than beta-YO greater than (-)IQ greater than DHC. Based on the potency ratio between alpha-1 and alpha-2 blocking activities, DHC or YO was most selective for alpha-1 or alpha-2 subtype, respectively, among the four YO analogs.(ABSTRACT TRUNCATED AT 250 WORDS)
Chemical composition of Aspidosperma ulei Markgr. and antiplasmodial activity of selected indole alkaloids.[Pubmed:23760029]
Molecules. 2013 May 29;18(6):6281-97.
A new indole alkaloid, 12-hydroxy-N-acetyl-21(N)-dehydroplumeran-18-oic acid (13), and 11 known indole alkaloids: 3,4,5,6-tetradehydro-beta-Yohimbine (3), 19(E)-hunteracine (4), beta-Yohimbine (5), yohimbine (6), 19,20-dehydro-17-alpha-yohimbine (7), uleine (10), 20-epi-dasycarpidone (11), olivacine (8), 20-epi-N-nor-dasycarpidone (14), N-demethyluleine (15) and 20(E)-nor-subincanadine E (12) and a boonein delta-lactone 9, ursolic acid (1) and 1D,1O-methyl-chiro-inositol (2) were isolated from the EtOH extracts of different parts of Aspidosperma ulei Markgr. (Apocynaceae). Identification and structural elucidation were based on IR, MS, (1)H- and (1)(3)C-NMR spectral data and comparison to literature data. The antiplasmodial and antimalarial activity of 1, 5, 6, 8, 10 and 15 has been previously evaluated and 1 and 10 have important in vitro and in vivo antimalarial properties according to patent and/or scientific literature. With the aim of discovering new antiplasmodial indole alkaloids, 3, 4, 11, 12 and 13 were evaluated for in vitro inhibition against the multi-drug resistant K1 strain of the human malaria parasite Plasmodium falciparum. IC(5)(0) values of 14.0 (39.9), 4.5 (16.7) and 14.5 (54.3) mg/mL (mM) were determined for 3, 11 and 12, respectively. Inhibitory activity of 3, 4, 11, 12 and 13 was evaluated against NIH3T3 murine fibroblasts. None of these compounds exhibited toxicity to fibroblasts (IC(5)(0) > 50 mg/mL). Of the five compounds screened for in vitro antiplasmodial activity, only 11 was active.
